Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.39 |
| ▸ | HTR1A | P08908 | 7/20 | 0.39 |
| ▸ | DRD2 | P14416 | 7/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014956 | 0.82 | OPRM1 (0.36) | OPRM1ALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL6014950 | 0.80 | MAPT (0.42) | ALDH1A1KDM4ESMN1; SMN2MEN1NPC1 | |
| SCHEMBL5779088 | 0.67 | KMT2A (0.40) | HTR1AALDH1A1KDM4ESMN1; SMN2HIF1A | |
| SCHEMBL29933722 | 0.64 | MAPT (0.55) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL12396131 | 0.64 | MAPT (0.55) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL4045158 | 0.61 | MEN1 (0.37) | OPRM1OPRL1ALDH1A1MEN1NPC1 | |
| SCHEMBL4040155 | 0.61 | GRIA1 (0.42) | DRD2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL6014993 | 0.61 | CA12 (0.52) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| Methsuximide SCHEMBL34853 | 0.59 | CYP19A1 (0.70) | ALDH1A1LMNAMEN1KMT2A | |
| Methsuximide SCHEMBL34852 | 0.59 | CYP19A1 (0.70) | ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | claimed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | claimed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | HTR7 266/4885HTR1A 268/4885DRD2 849/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | HTR7 287/4885HTR1A 216/4885DRD2 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.